Yan Zhang1,
Haifeng Liu2,
Ying Wang2,
Chenggang Sun3 
For correspondence:- Chenggang Sun Email: Chenggangdr@outlook.com
Accepted: 14 August 2022 Published: 30 September 2022
Citation: Zhang Y, Liu H, Wang Y, Sun C. Comparison of efficacy and safety of three different drugs combined with radiotherapy in the treatment of patients with advanced pancreatic cancer. Trop J Pharm Res 2022; 21(9):2017-2024 doi: 10.4314/tjpr.v21i9.28
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the clinical efficacy and safety of three different drugs combined with radiotherapy, viz, apatinib mesylate combined radiotherapy (group A), gemcitabine combined oxaliplatin (group B), and Huachansu capsules combined radiotherapy (group C)] in advanced pancreatic cancer patients.
Methods: A total of 174 patients with advanced pancreatic cancer treated in Yantai Qishan Hospital, Yantai, China from June 2015 to December 2016 were randomly and evenly divided into groups A, B, and C. The incidence of adverse reactions during treatment, immune reaction, efficacy, quality of life, and survival were compared among the three groups after four courses of treatment.
Results: Compared with groups B and C, the incidence of nausea and vomiting was higher in group A (p < 0.05), but the incidence of other adverse events was not significantly different (p > 0.05). Group A showed higher response rate and disease control rate, higher CD4+, CD4+/CD8+ levels and QOL scores, as well as lower CD8+ level in peripheral blood after treatment than groups B and C (p < 0.05). Group A also exhibited longer median OS and median PFS, and higher 2-year survival than groups B and C (p < 0.05).
Conclusion: Among the three different drug treatments combined with radiotherapy, apatinib mesylate combined radiotherapy enhanced efficacy and quality of life, and lengthen the survival time of advanced pancreatic cancer patients. However, additional clinical trials are required to validate these findings.
Archives
News Updates
Fulltext in PDF